Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care.

Publication date: Mar 19, 2020

Melanoma cancer is an important public health concern owing to its prevalence, high recurrence risk, treatment failures and immunosuppressive abilities. Prolonged immune system activation is the main objective of immune checkpoint inhibitors (ICIs) therapies directed against melanoma cancer. Despite the staggering advancements in approved ICIs therapy effectiveness, immune-related adverse events (imAEs) and therapeutic resistance has limited its wide application. Thus, there is a need to establish biomarkers that predict the response to ICIs and imAEs. In this review article, we provide an in-depth understanding of the role of tolerance, immunity, and immunosuppression in antitumor immune response regulation, together with ongoing clinical therapy and suggested biomarkers. These attainments advise that approved ICIs provide a novel approach to durable and prolonged response in cancer patients and will aid in the reduction of treatment cost and duration and enhance patient recovery.

Singh, S., Numan, A., Agrawal, N., Tambuwala, M.M., , Singh, and Kesharwani, P. Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care. 26203. 2020 Int Immunopharmacol (83):

Concepts Keywords
Biomarkers Melanoma care
Cancer Melanoma cancer
Immune System Melanoma care Melanoma
Immunity Immunosuppression
Immunosuppression Medicine
Immunosuppressive Immune system
Melanoma Medical specialties
Clinical medicine
Checkpoint inhibitor
Immune checkpoint
Treatment of cancer


Type Source Name
disease MESH melanoma
pathway KEGG Melanoma
disease MESH cancer
disease MESH recurrence
disease MESH treatment failures


Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *